Total combined orders for delivery for Creso Pharma (ASX: CPH) now over $1M
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Creso Pharma Limited (ASX:CPH; FRA:1X8) continues to build a strong revenue platform for 2021, advising today that it has received two new purchase orders (POs) for its anibidiol® line of animal health products totalling A$247,826 (CHF171,000).
The above purchase order total is composed of a new PO from the new commercial partner for LATAM Medara/Adler of A$86,957 (CHF60,000) and a follow-up PO of A$256,470 (CHF171,600) from current commercial partners.
These orders come less than a week after Creso Pharma confirmed that it had ‘’banked’’ $320,000 following the delivery of a second shipment of cannaQIX® products to the subsidiary of Lupin International (NYSE: LUPIN), Pharma Dynamics South Africa.
Together, the total value of combined orders represents CHF728,000 (A$1,055,0721) which Creso Pharma expects to recognise as revenue within the first half of FY2021. This is a major achievement for the Company and highlights the growing demand that it is witnessing for its leading product ranges on a global scale.
The purchase orders underpin the strong demand growth for the company’s industry leading products and the first geographic expansion result in Southern LATAM starting in Uruguay.
This sets the basis for rapid growth into further LATAM countries, Argentina, Paraguay, Chile, Bolivia and beyond.
While Creso Pharma is broadening its areas of distribution, the company uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland.
The company has worldwide rights for a number of unique and proprietary innovative delivery technologies that enhance the bioavailability and absorption of cannabinoids.
Creso Pharma negotiates regulatory guidelines as conditions improve
The orders announced today are a significant achievement for Creso Pharma, highlighting the company’s ability to navigate stringent regulatory requirements for marketing hemp products across Europe, as well as reaffirming management’s ability to progress growth initiatives in difficult market conditions.
The demand for the products remains high and these POs serve as further confirmation of the success of the anibidiol® product line in the rapidly growing European and LATAM animal health market.
The product uptake since 2017 continues, totalling over 4 million anibidiol® doses in purchase orders.
Creso is continuing to explore plans to expand its animal health portfolio with additional innovative products such as various hemp-flour and hemp seed oil products.
With growing demand for its existing products, management is also progressing strategies to increase its footprint in the sector.
Commenting on Creso Pharma’s ability to quickly scale up its operations to meet increasing demand, commercial director Dr. Gian Trepp said, “We are very pleased by the PO developments from current and new customers.
‘’Our capabilities to supply the products in spite of the current very challenging COVID situation in a fast and flexible way is a key success factor.
‘’These capabilities and the newly enlarged product portfolio places Creso in a favorable position to respond best to the fast-growing demand and benefit from new animal health opportunities to grow its footprint in this space.”
tagsPURCHASE ORDERS ANIBIDIOL OVER 4 MILLION ANIBIDIOL DOSES STRONG DEMAND GROWTH ANIMAL HEALTH PRODUCTS
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.